CAS Number103577-45-3
Synonyms2-({[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl}sulfinyl)-1H-benzimidazole; Ogast; Agopton; Lanz; Promp; Limpidex; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; Ulpax; Takepron; 2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole; MFCD00866873; Zoton; 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole; 2-({[3-Methyl-4-(2,2,2-trifluorethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazol; Lansox; Prevacid; Ketian; Lansoprazole; Lanzor; Lancid
Molecular FormulaC16H14F3N3O2S
Molecular Weight369.36
Purity98%
Density1.5±0.1 g/cm3
Boiling Point555.8±60.0 °C at 760 mmHg
Melting Point178-182°C dec.
AppearanceWhite crystalline powder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 103577-45-3 |
| Catalog No. | 2A-9011124 |
| Chinese Name | 兰索拉唑 |
| Synonyms | 2-({[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl}sulfinyl)-1H-benzimidazole; Ogast; Agopton; Lanz; Promp; Limpidex; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; Ulpax; Takepron; 2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole; MFCD00866873; Zoton; 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole; 2-({[3-Methyl-4-(2,2,2-trifluorethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazol; Lansox; Prevacid; Ketian; Lansoprazole; Lanzor; Lancid |
| Molecular Formula | C16H14F3N3O2S |
| Molecular Weight | 369.36 |
| Purity | 98 |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 555.8±60.0 °C at 760 mmHg |
| Melting Point | 178-182°C dec. |
| Appearance | White crystalline powder |
| Storage Condition | Protect from light, airtight, and store at low tem |
| Application | Lansoprazole (AG-1749) is a proton pump inhibitor that inhibits gastric acid production. |
| HTC | 2933990090 |
| MDL Number | MFCD00866873 |
| SMILES | Cc1c(CS(=O)c2nc3ccccc3[nH]2)nccc1OCC(F)(F)F |
| InChI | 1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22) |
| InChI Key | MJIHNNLFOKEZEW-UHFFFAOYSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| Hazard Symbols | Transport |
| MSDS | msds/11124_1_103577_45_3.pdf |
| Bioactivity | Lansoprazole(AG 1749) is a proton pump inhibitor which prevents the stomach from producing acid.Target: Proton PumpLansoprazole, a substituted benzimidizole proton pump inhibitor, on pharmacokinetics and metabolism of theophylline has been studied in healthy adults given oral lansoprazole 30 mg once daily for 11 days. On Days 4 and 11 of 300 mg aminophylline was simultaneously administered orally and blood samples for theophylline analysis were taken over 24 h [1]. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups [2]. lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 micrograms/ml, and fourfold more potent than that of omeprazole [3]. Clinical indications: Duodenal ulcer; Esophagitis; Gastroesophageal reflux; Gastrointestinal disease; Helicobacter pylori infection; Peptic ulcer; Stomach ulcer; Ulcer; Zollinger-Ellison syndromeFDA Approved Date: May 10, 1995Toxicity: Symptoms of overdose include abdominal pain, nausea and diarrhea. Related Catalog Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump Research Areas >> Inflammation/Immunology References [1]. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5. [2]. Lai, K.C., et al., Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med, 2002. 346(26): p. 2033-8. [3]. Iwahi, T., et al., Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother, 1991. 35(3): p. 490-6. Chemical & Physical Properties Density 1.5±0.1 g/cm3 Boiling Point 555.8±60.0 °C at 760 mmHg Melting Point 178-182°C dec. Molecular Formula C16H14F3N3O2S Molecular Weight 369.362 Flash Point 289.9±32.9 °C Exact Mass 369.075867 PSA 87.08000 LogP 2.76 Vapour Pressure 0.0±1.5 mmHg at 25°C Index of Refraction 1.635 InChIKey MJIHNNLFOKEZEW-UHFFFAOYSA-N SMILES Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1 Storage condition 2-8°C |
| Use of | Properties Articles50 Name lansoprazole Synonym More Synonyms Lansoprazole Biological Activity Related Catalog Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump Research Areas >> Inflammation/Immunology References [1]. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5. [2]. Lai, K.C., et al., Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med, 2002. 346(26): p. 2033-8. [3]. Iwahi, T., et al., Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother, 1991. 35(3): p. 490-6. Chemical & Physical Properties Molecular Formula C16H14F3N3O2S Exact Mass 369.075867 PSA 87.08000 Index of Refraction 1.635 InChIKey MJIHNNLFOKEZEW-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| LaBetalol | 36894-69-6 | 2A-9011109 |
| LaBetalol hydrochloride | 32780-64-6 | 2A-9011110 |
| Lacidipine | 103890-78-4 | 2A-9011112 |
| Lamivudine | 134678-17-4 | 2A-9011118 |
| Lamotrigine | 84057-84-1 | 2A-9011119 |
| Lansoprazole Sulphide compound | 103577-40-8 | 2A-9011125 |
| Letrozole | 112809-51-5 | 2A-9011156 |
| Levodopa | 59-92-7 | 2A-9011171 |
| Levofloxacin | 100986-85-4 | 2A-9011173 |
| levofloxacin Mesylate | 226578-51-4 | 2A-9011174 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS